Lawrence B Berk

Summary

Affiliation: H. Lee Moffitt Cancer Center and Research Institute
Country: USA

Publications

  1. ncbi A randomized, double-blind, placebo-controlled trial of a beta-hydroxyl beta-methyl butyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (RTOG 0122)
    Lawrence Berk
    Moffitt Cancer Center at Tampa General Hospital, 2 Columbia Dr, Tampa, FL 33606, USA
    Support Care Cancer 16:1179-88. 2008
  2. ncbi Radiation therapy as primary and adjuvant treatment for local and regional melanoma
    Lawrence B Berk
    Radiation Oncology Program, Moffitt Cancer Center at Tampa General Hospital, FL 33606, USA
    Cancer Control 15:233-8. 2008
  3. ncbi Systemic pilocarpine for treatment of xerostomia
    Lawrence Berk
    Moffitt Cancer Center at Tampa General Hospital, Moffitt Cancer Center, Radiation Oncology, 2 Columbia Dr, Tampa, FL 33606, USA
    Expert Opin Drug Metab Toxicol 4:1333-40. 2008
  4. ncbi Systemic therapy for advanced hepatocellular carcinoma: past, present, and future
    Jennifer L Giglia
    Gastrointestinal Tumor Program, Moffitt Cancer Center, Tampa, FL 33612, USA
    Cancer Control 17:120-9. 2010
  5. ncbi Treatment options for limited or symptomatic metastatic melanoma
    James M McLoughlin
    Cutaneous Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 15:239-47. 2008
  6. ncbi Assessment of quality of life and oral function of patients participating in a phase II study of radioprotection of oral and pharyngeal mucosa by the prostaglandin E(1) analog misoprostol (RTOG 96-07)
    Darlene J Johnson
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, FL 33612, USA
    Int J Radiat Oncol Biol Phys 54:1455-9. 2002
  7. ncbi Pathophysiology and management of radiation-induced xerostomia
    Lawrence B Berk
    Newark Radiation Oncology, Newark, Ohio, USA
    J Support Oncol 3:191-200. 2005

Collaborators

Detail Information

Publications7

  1. ncbi A randomized, double-blind, placebo-controlled trial of a beta-hydroxyl beta-methyl butyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (RTOG 0122)
    Lawrence Berk
    Moffitt Cancer Center at Tampa General Hospital, 2 Columbia Dr, Tampa, FL 33606, USA
    Support Care Cancer 16:1179-88. 2008
    ..Therefore a phase III trial was implemented to confirm this activity...
  2. ncbi Radiation therapy as primary and adjuvant treatment for local and regional melanoma
    Lawrence B Berk
    Radiation Oncology Program, Moffitt Cancer Center at Tampa General Hospital, FL 33606, USA
    Cancer Control 15:233-8. 2008
    ..The role of radiation therapy as primary and adjuvant therapy for localized or locally advanced melanoma is controversial...
  3. ncbi Systemic pilocarpine for treatment of xerostomia
    Lawrence Berk
    Moffitt Cancer Center at Tampa General Hospital, Moffitt Cancer Center, Radiation Oncology, 2 Columbia Dr, Tampa, FL 33606, USA
    Expert Opin Drug Metab Toxicol 4:1333-40. 2008
    ..The primary treatment to reduce xerostomia is oral pilocarpine...
  4. ncbi Systemic therapy for advanced hepatocellular carcinoma: past, present, and future
    Jennifer L Giglia
    Gastrointestinal Tumor Program, Moffitt Cancer Center, Tampa, FL 33612, USA
    Cancer Control 17:120-9. 2010
    ..While responses to traditional chemotherapeutic agents have been documented, significant survival benefit is debatable...
  5. ncbi Treatment options for limited or symptomatic metastatic melanoma
    James M McLoughlin
    Cutaneous Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 15:239-47. 2008
    ..Patients who develop metastatic melanoma often have limited effective treatment options. However, a select group of patients will benefit from aggressive surgery or a multidisciplinary approach, depending on the site of metastasis...
  6. ncbi Assessment of quality of life and oral function of patients participating in a phase II study of radioprotection of oral and pharyngeal mucosa by the prostaglandin E(1) analog misoprostol (RTOG 96-07)
    Darlene J Johnson
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, FL 33612, USA
    Int J Radiat Oncol Biol Phys 54:1455-9. 2002
    ..We report the results of the QOL outcomes of patients in this study...
  7. ncbi Pathophysiology and management of radiation-induced xerostomia
    Lawrence B Berk
    Newark Radiation Oncology, Newark, Ohio, USA
    J Support Oncol 3:191-200. 2005
    ....